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Variable Min Max
Symptomatic patients who had CAS (vs CEA), % 7 32
Asymptomatic patients who had
CAS (vs CEA), %
7 23
CEA with symptoms, % 20 42
CAS with symptoms, % 10 53
CEA with patch, % 73 95
CEA with shunt use, % 33 76
CEA where EEG used by surgeons who
routinely shunt, %
0 68
CAS on both antiplatelet and statin, % 60 82
CAS discharged on both antiplatelet and statin, % 75 91
Asymptomatic CAS with stenosis >70%, % 67 97
CAS predialated, % 27 68
CAS postdialated, % 60 96
All P < .01.PS116.
Are NASCET and ACAS Guidelines Applicable to
Modern Imaging Measurements: Digital Subtraction
Angiography vs TeraRecon CTA
Ashley Aaron, Adithya Suresh, Steven Santilli, Rumi Faizer,
Steven Levin. University of Minnesota, St. Paul, Minn
Objectives: The North American Symptomatic Ca-
rotid Endarterectomy Trial (NASCET) and Asymptomatic
Carotid Artery Surgery Trial, helped establish guidelines
for carotid intervention based on conventional angiography
measurements of stenosis. However, with improvement in
noninvasive imaging techniques, the use of computed to-
mography angiography (CTA) has become widespread.
The goal of this retrospective evaluation was to compare
the degree of carotid stenosis based on TeraRecon
compared with angiography and how these potential differ-
ences may impact decisions for intervention.
Methods: The percentage of carotid stenosis was ob-
tained via digital subtraction angiography and TeraRecon.
The study population included 58 patients who underwent
carotid artery stenting for symptomatic and asymptomatic ca-
rotid stenosis between 2006 and 2013. The TeraRecon CTA
and angiography stenosis measurements were analyzed by
Student t-test to determine if traditional NASCET angiog-
raphy determinations for intervention are applicable to CTA.
Results: TeraRecon CTA measurements of the per-
centage of carotid artery stenosis were, on average, 6.5%
higher than those based on angiography. Analysis with
the Student t-test showed a statistically signiﬁcant differ-
ence between the two measurements (P ¼ .0033).
Conclusions: Overall, we found that measurements of
percent carotid artery stenosis in asymptomatic and symp-
tomatic patients undergoing carotid stent placement were
higher when using TeraRecon CTA compared with mea-
sures with angiography. This prompts the question have
we been over-intervening on patients by using NASCET
and ACAS guidelines on patients imaged with CTA?
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Regional Differences in Patient Selection and
Treatment of Carotid Artery Disease in the Society
for Vascular Surgery Vascular Quality Initiative (SVS
VQI)
John C. McCallum1, Thomas Curran1, Dominique B.
Buck1, Jeremy D. Darling1, Joe Schneider3, Brian W.
Nolan2, Philip P. Goodney2, Marc L. Schermerhorn1.
1Vascular Surgery, Beth Israel Deaconess Medical Center,
Boston, Mass; 2Dartmouth Hitchcock Medical Center,
Hanover, NH; 3Northwestern University Feinberg
School of Medicine, Chicago, IllObjectives: There are limited data on the regional
variation of carotid endarterectomy (CEA) and carotid
stenting (CAS). We use the Society for Vascular Surgery
Vascular Quality Initiative (SVS-VQI) to evaluate regional
differences in CEA and CAS across the United States.
Methods: We used the SVS-VQI to identify pa-
tients undergoing CEA and CAS between 2009 and
2012. Each of 14 regions was evaluated. Regions per-
forming <50 CAS were excluded, leaving nine regions.
Results: A total of 14,871 cases were performed, and a
minority of cases used CAS (vs CEA) to treat both symptom-
atic and asymptomatic disease. Substantial regional variation in
patient characteristics (eg, symptom status, stenosis >70%),
technical approach (eg, CEA vs stent, patch use, shunt use,
neurologic monitoring, cerebral protection device use and
type), and evidence-based process measures (eg, antiplatelet
and statin use, patch use) are demonstrated in the Table.
Conclusions: This ﬁrst investigation of a national clin-
ical database demonstrates signiﬁcant regional variation in
carotid disease management. Future studies on the associ-
ation of regional variation with risk-adjusted outcomes
offer the opportunity for quality improvement through
prospective identiﬁcation of best practices.Author Disclosures: D. B. Buck: Nothing to disclose; T.
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Outcomes After Early and Delayed Carotid
Endarterectomy in Patients With Symptomatic
Carotid Artery Stenosis
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Endovascular Surgery, Mayo Clinic, Rochester, Minn
Objectives: To deﬁne outcomes after carotid endar-
terectomy (CEA) in symptomatic patients when operated
on #14 days after onset of symptoms or later (<14 days).
Methods: Clinical data of consecutive patients who
underwent CEA (2003-2012) for symptomatic carotid
